The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy.

Inclusion Criteria:

• documented diabetic nephropathy in patients with either Type 1 or Type 2 diabetics
• HbA1c of 7.5-10.5%
• eGFR 30-110 mL/min/1.73m2
• stable ACEi/ARB dose regimen
• stable blood pressure
• BMI less than or equal to 45 kg/m2

Exclusion Criteria:

• non-diabetic renal disease
• history of solid organ or islet cell transplant
• history of malignancy within previous 5 years
• systemic immunosuppression therapy
• clinically significant liver disease, hepatitis B or C or HIV
• monoclonal antibody treatment within previous year
• recent acute renal injury or major surgery
• significant, recent body weight change
• biopsy proven glomerular disease